Fig. 7
From: A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
TIGIT-28 mediates superior anti-tumor cytotoxicity in xenograft models. a TIGIT-28/F4 or Ctrl/F4 transduced T-cells were co-cultured with the indicated target cell lines for 4 h at different E:T ratios (as indicated). Release of lactate dehydrogenase as a measure of cytotoxicity was analyzed as described in the Material and Methods section and normalized to that of target cells incubated with Triton X 100(9%). These results are representative of three independent experiments with three different donors and no significant different was noted between the TCR only group (Ctrl F4) and F4 + TIGIT28. b-c NSG mice inoculated with SK-MEL23/155 tumor cells and treated with TIGIT-28/F4, F4 TCR only (Ctrl/F4) T-cells or mock transduced T-cells (Ctrl.). (B) Tumor growth was measured in a blinded fashion using a caliper and calculated using the following formula: (Dxd2)xΠ/6, where D is the largest tumor diameter and d its perpendicular one. Results are shown for the different time points as mean + SEM (n = 10) and the difference between the TIGIT-28 and Ctrl-treated groups was found statistically significant (ANOVA; p = 4.2e-05). (C) The percentage survival per treated group was determined on a daily basis and is represented by Kaplan-Meier survival curve. The difference between the TIGIT-28 + F4 and F4 only-treated groups was found statistically significant (Logrank test; p = 0.0006)